In a study published in Science Translational Medicine, a team of researchers led by Dr. Wang Yu from the Shenzhen Institutes ...
Is NTLA a good stock to buy? We came across a bullish thesis on Intellia Therapeutics, Inc. on Markman Capital Insight’s ...
CRISPR Therapeutics stock has rebounded in the short term; however, over five years the share price is still significantly ...
Morning Overview on MSN
The first baby treated with a custom CRISPR therapy is thriving a year later
One year after receiving three doses of a custom-built CRISPR base-editing therapy at Children’s Hospital of Philadelphia, ...
Morning Overview on MSN
A single gene-editing infusion cut severe swelling attacks by 87 percent in a trial
People living with hereditary angioedema, a rare genetic condition that triggers sudden, painful swelling of the face, throat ...
CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.
Researchers have spent decades—and billions of dollars—sequencing animal and crop genomes, but fungi have historically been the forgotten middle child of genomics, only noticed when they're ruining ...
The FDA on Wednesday expanded the approval for exagamglogene autotemcel (exa-cel, Casgevy) in severe sickle cell disease with ...
Daniel Cressy, 23, has become the first person in the Gulf South to become functionally cured of sickle cell disease using ...
Scribe Therapeutics filed for an initial public offering. The biotechnology company didn't say how many shares it would offer or at what price, and said the underwriters have a 30-day option to buy ...
Teetering near endangered status, the starlet sea anemone produces “an ancient mechanism” for fighting viruses that ...
Genetic profiles and gene editor CRISPR threaten to bring a new eugenics of gene selection. Even eugenicist Foster Kennedy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results